Biocon's Biosimilar Blues


Biocon’s recent acquisition of its partner Viatris Inc.'s biosimilar business has shocked the investors as the company’s shares fell nearly 12% on the bourses. Host Dia Rekhi along with Biocon Biologics’ Deputy CEO Shreehas Tambe, ET’s Kiran Somvanshi, and ET Prime’s Vikas Dandekar break down the deal means for the company and the investors and whether the $3.3-billion bet is worth the risk? Credits: ET Now

Rate article

Subscribe to our newsletter today

India's new audio destination for business news and more. Brought to you by The Economic Times.

@2024 BCCL. All Rights Reserved